Olanzapina Ratiopharm (Olanzapine)

Olanzapina Ratiopharm is an atypical antipsychotic used in psychiatric disorders that affect dopamine and serotonin pathways.

• Schizophrenia: helps reduce psychotic symptoms such as hallucinations and delusions.
• Bipolar I disorder (manic episodes): assists in stabilising mood and decreasing manic symptoms.
• Maintenance therapy for schizophrenia or bipolar disorder: supports long‑term symptom control and relapse prevention.

• Olanzapine acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, with additional affinity for several other neurotransmitter receptors. By blocking these receptors, it reduces dopaminergic and serotonergic activity that underlies psychotic and mood‑stabilising effects, helping to normalize neurotransmission in the brain.

Olanzapina Ratiopharm may produce a range of adverse reactions, from mild to serious.

Common Side Effects

• Weight gain
• Sedation
• Dry mouth
• Constipation
• Increased appetite
• Dizziness

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe hyperglycaemia
• Agranulocytosis
• Seizures
• Elevated prolactin levels

When prescribing Olanzapina Ratiopharm, clinicians should consider several safety aspects.

• Monitor metabolic parameters: regularly check weight, fasting glucose, and lipid profile.
• Assess for extrapyramidal symptoms: watch for signs of movement disorders.
• Evaluate cardiac health: consider ECG monitoring in patients with cardiac risk factors.
• Use caution in hepatic impairment: dose adjustments may be required.
• Avoid abrupt discontinuation: taper gradually to reduce withdrawal effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olanzapina Ratiopharm can interact with a variety of medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase olanzapine levels.
• CNS depressants (e.g., benzodiazepines, opio opio­​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​):

Moderate   -   -   -